Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Intravenous versus subcutaneous immunoglobulin - Authors' reply.

van Schaik IN, Mielke O; PATH study group.

Lancet Neurol. 2018 May;17(5):393-394. doi: 10.1016/S1474-4422(18)30109-1. No abstract available.

PMID:
29656738
2.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26.

PMID:
29122523
3.

Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.

Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V.

Int J Cancer. 2016 Oct 15;139(8):1776-87. doi: 10.1002/ijc.30234. Epub 2016 Jul 7.

4.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

5.

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group.

Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

PMID:
21571593
6.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

7.

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.

Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I.

Mult Scler. 2007 Nov;13(9):1107-17. Epub 2007 Jul 10.

PMID:
17623736
8.

Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis.

Woessner R, Grauer MT, Frese A, Bethke F, Ginger T, Hans A, Treib J.

Infection. 2006 Dec;34(6):342-4.

PMID:
17180590
9.

Conducting without memory - a case report on transient global amnesia.

Evers S, Frese A, Bethke F.

Eur J Neurol. 2002 Nov;9(6):695-6. No abstract available.

PMID:
12453094
10.

Event-related potentials in different subtypes of multiple sclerosis--a cross-sectional study.

Ellger T, Bethke F, Frese A, Luettmann RJ, Buchheister A, Ringelstein EB, Evers S.

J Neurol Sci. 2002 Dec 15;205(1):35-40.

PMID:
12409181
11.

Therapy of Sneddon syndrome.

Flöel A, Imai T, Lohmann H, Bethke F, Sunderkötter C, Droste DW.

Eur Neurol. 2002;48(3):126-32.

PMID:
12373028
12.

Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.

Frese A, Bethke F, Lüdemann P, Stögbauer F.

J Neurol. 2000 Sep;247(9):713. No abstract available.

PMID:
11081814
13.

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.

Frese A, Bethke F, Lüdemann P, Stögbauer F.

Neurology. 1999 Nov 10;53(8):1892-3. No abstract available.

PMID:
10563657
14.

Human herpesvirus 8 cellular immune responses in homosexual men.

Strickler HD, Goedert JJ, Bethke FR, Trubey CM, O'Brien TR, Palefsky J, Whitman JE, Ablashi D, Zeichner S, Shearer GM.

J Infect Dis. 1999 Nov;180(5):1682-5.

PMID:
10515832
15.

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.

Poehlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L, Haas J, Przuntek H.

Mult Scler. 1997 Apr;3(2):149-52.

PMID:
9291171
16.

In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients.

Lucey DR, Pinto LA, Bethke FR, Rusnak J, Melcher GP, Hashemi FN, Landay AL, Kessler HA, Paxton RJ, Grabstein K, Shearer GM.

Clin Diagn Lab Immunol. 1997 Jan;4(1):43-8.

17.

Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL.

J Immunol. 1995 Oct 15;155(8):4100-10.

PMID:
7561123
18.

Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules.

VanCott TC, Bethke FR, Kalyanaraman V, Burke DS, Redfield RR, Birx DL.

J Acquir Immune Defic Syndr. 1994 Nov;7(11):1103-15.

PMID:
7523653
19.

Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.

VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL.

J Immunol. 1994 Jul 1;153(1):449-59.

PMID:
7515931
20.

Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop).

Lucey DR, VanCott TC, Loomis LD, Bethke FR, Hendrix CW, Melcher GP, Redfield RR, Birx DL.

J Acquir Immune Defic Syndr. 1993 Sep;6(9):994-1001.

PMID:
7688046

Supplemental Content

Loading ...
Support Center